The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience
Introduction Recently published case reports suggest the benefit of empagliflozin use in subjects with glycogen storage disease Ib (GSD Ib). Material and methods We present the clinical and laboratory data of 2 adult brothers with GSD Ib treated with empagliflozin for 12 months. Results There was...
Main Authors: | Joanna Bidiuk, Zbigniew A. Gaciong, Piotr Sobieraj |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2022-06-01
|
Series: | Archives of Medical Science |
Subjects: | |
Online Access: | https://www.archivesofmedicalscience.com/The-overall-benefits-of-empagliflozin-treatment-in-adult-siblings-with-glycogen-storage,150029,0,2.html |
Similar Items
-
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
by: Arianna Maiorana, et al.
Published: (2023-04-01) -
Glycogen storage disease type Ib: modern understanding of the pathogenesis of neutropenia and prospects for its treatment with empagliflozin
by: Andrej N. Surkov, et al.
Published: (2023-11-01) -
Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study
by: Sarah C. Grünert, et al.
Published: (2023-05-01) -
Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study
by: Yong-Xian Shao, et al.
Published: (2024-04-01) -
Liver transplantation in glycogen storage disease type Ib: The role of SGLT2 inhibitors
by: Simona Murko, et al.
Published: (2023-06-01)